Telomir Pharmaceuticals Inc (NASDAQ: TELO) is a clinical-stage pharmaceutical company developing Telomir-1, a drug candidate targeting aging-related conditions including insulin resistance, hyperglycemia, and Wilson's disease. The company has no approved products and generates no product revenue as of the fiscal year ended December 31, 2025. Telomir-1 is the sole pipeline asset disclosed in the 10-K filed March 17, 2026. Research and development activities are conducted entirely through outside contractors and manufacturers. For FY2025, the company reported a net operating cash outflow of $3.7 million and a net cash inflow from financing activities of $9.7 million, indicating it funds operations through equity and debt raises rather than commercial sales. The company has disclosed going-concern uncertainty, with continued operations dependent on securing additional financing. A pending merger with TELI Pharmaceuticals, Inc. (a private Delaware company) is expected to consolidate U.S. and non-U.S. rights to Telomir-1 within a single public structure, per the Agreement and Plan of Merger dated November 20, 2025, as amended February 4, 2026.

Revenue model

No product revenue disclosed as of FY2025. Operations are funded through equity and debt financing. Net cash inflow from financing activities was $9.7 million in FY2025 and $6.3 million in FY2024.

Products and services

Telomir-1: a single drug candidate in development for aging-related conditions including insulin resistance, hyperglycemia, and Wilson's disease. Preclinical data cited in the 10-K include dose-dependent normalization of blood glucose, reduced HOMA-IR values, improved OGTT results, increased survival rates, and enhanced mobility in older organisms.

Customers and end markets

No commercial customers disclosed. Target end market is pharmaceutical therapeutics for metabolic and aging-related conditions, subject to third-party payer formulary inclusion and reimbursement coverage upon any future approval.

Value-chain role

Drug developer reliant on contract manufacturers and outside contractors for all research, development, and manufacturing activities. No proprietary manufacturing facilities disclosed.

Geographic exposure

U.S.-focused regulatory and operational activity. Pending merger with TELI Pharmaceuticals is described as consolidating U.S. and non-U.S. rights to Telomir-1, implying some international rights exist but no specific geographic revenue mix is disclosed.

Source: SEC 10-K, filed 2026-03-17

Industry: Pharmaceutical Preparations Peers: Amylyx Pharmaceuticals Inc LeonaBio Inc Eli Lilly and Co OptiNose, Inc. Ventyx Biosciences, Inc.